One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome

Inclusion Criteria:

• Subject must present at least 2 of the following risk factors of MS at screening: Elevated waist circumference: >102 cm in men and >88 cm in women; Elevated triglycerides (TGs): ?1.7 mmol/L (?150 mg/dL); Reduced HDL-Cholesterol: <1.03 mmol/L (<40 mg/dL) in men and <1.3 mmol/L (<50 mg/dL) in women; Elevated fasting glucose: ? 5.6 mmol/L.
• According to the clinical judgment of the investigator, the risk factors for MS have developed in close temporal relationship to starting an antipsychotic medication.
• Substitution to a less metabolically disruptive antipsychotic medication is considered

Exclusion Criteria:

• Subjects with contraindication(s) to the use of Ziprasidone according to Canadian prescribing information.
• Subjects with a history of treatment resistance.
• Subjects with any medical condition (e.g. pre-existing diabetes, pre-existing dyslipidemia, thyroid pathology) or taking any concomitant medication (e.g. topiramate or other weight loss-promoting agents, hypoglycemic agents, hypolipemic agents), that may confound the evaluation of the study drug.
• Body mass index ? 40 at baseline.